Early detection is crucial to the chances of survival in lung cancer: whilst 55 per cent of patients with stage I lung cancer survive the first five years after diagnosis, the figure is less than five per cent among those with tumours at the advanced stage IV. Heavy smokers are particularly at risk, although preventive measures such as computed tomography (CT) scans are effective in detecting lung cancer at a very early stage, thereby reducing lung cancer mortality by up to 30 per cent. However, to minimise side effects, it would be desirable to be able to use CT scans for early detection in a more targeted manner among high-risk groups. A team led by lead author Megha Bardwaj from the DKFZ in Heidelberg has now investigated whether inflammatory markers that can be measured in the blood can improve the accuracy of predicting lung cancer risk. To this end, they selected a panel of 92 biomarkers, including numerous cytokines and interleukins that can be detected in a tiny sample volume of just one microlitre of blood. For the current study, the research team analysed blood samples from 172 participants in the ESTHER study who had been diagnosed with lung cancer, as well as from 285 other study participants – smokers or former smokers – who had not developed lung cancer. The researchers combined the analysis of inflammatory markers with a variety of commonly used risk calculations based on known risk factors for lung cancer. In all cases, the combined approach yielded more accurate predictions, thereby significantly improving the prediction of lung cancer risk. Further studies are now planned to confirm these results, and additional blood markers are to be included in order to improve risk assessment even further. Reference: DKFZ Heidelberg Potential of Inflammatory Protein Signatures for Enhanced Selection of People for Lung Cancer Screening, Cancers 2022; https://www.mdpi.com/2072-6694/14/9/2146
Lung cancer: improved risk assessment